scholarly journals Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease

Aging ◽  
2020 ◽  
Vol 12 (14) ◽  
pp. 14528-14541
Author(s):  
Wei Xu ◽  
Bing-Jie Su ◽  
Xue-Ning Shen ◽  
Yan-Lin Bi ◽  
Chen-Chen Tan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Clinical Progression ◽  
Prodromal Alzheimer’S Disease

scholarly journals Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease

2019 ◽  
Author(s):  
Wei Xu ◽  
Bing-Jie Su ◽  
Xue-Ning Shen ◽  
Yan-Lin Bi ◽  
Chen-Chen Tan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Metabolism ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Clinical Progression ◽  
Cross Sectional ◽  
Prodromal Ad ◽  
Prodromal Alzheimer’S Disease

Abstract Background: Sex hormone-binding globulin (SHBG) in plasma has been found to be significantly elevated in subjects with AD. We aimed to investigate whether plasma SHBG was associated with AD biomarkers and could predict neurodegeneration and clinical progression in prodromal AD.Methods: The study tested the cross-sectional relationship between plasma SHBG and CSF AD biomarkers in 707 non-demented adults. Next, the longitudinal influences of plasma SHBG at baseline on dynamic changes of CSF Aβ42, hippocampus volume, brain metabolism, and cognition were explored in 448 non-demented adults from the Alzheimer’s disease Neuroimaging Initiative (ADNI). Finally, the influence of plasma SHBG on the risk of incident AD was explored. Results: This study included 707 participants (mean [SD] age, 62.5 [10.5] years, 416 [58.8%] female) from CABLE and 448 from ADNI-1 (mean [SD] age, 74.8 [7.2] years, 166 [37.5%] female). A positive correlation was found for SHBG levels in plasma and CSF (p = 2.12 × 10 -10, r = 0.44). Cross-sectional analyses indicated that individuals with higher plasma SHBG had lower levels of CSF Aβ42 (p < 0.005), after adjusting for age, gender, education, APOE4 allele, and cognitive scores. The longitudinal data showed that higher levels of plasma SHBG contribute to accelerated CSF Aβ42 decrease (p < 0.0005), brain metabolism decline (p < 0.05), hippocampus atrophy (p < 0.01), cognitive decline (p < 0.01), and higher risk of AD dementia (p < 0.05).Conclusions: Plasma SHBG is associated with CSF Aβ42 levels and could predict neurodegeneration and clinical progression in prodromal AD. This finding indicates plasma SHBG is a potentially useful, early biomarker for AD.

P4-044: Sex hormone binding globulin and incident Alzheimer's disease in elderly men and women

2008 ◽  
Vol 4 ◽  
pp. T681-T681
Author(s):  
Majon Muller ◽  
Nicole Schupf ◽  
Jennifer J. Manly ◽  
Richard Mayeux ◽  
José A. Luchsinger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Elderly Men ◽  
Men And Women

Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease

2004 ◽  
Vol 25 (2) ◽  
pp. 141-147 ◽  
Author(s):  
Elena K Hoskin ◽  
Ming X Tang ◽  
Jennifer J Manly ◽  
Richard Mayeux
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Elderly Women ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding

scholarly journals Sex hormone binding globulin and incident Alzheimer’s disease in elderly men and women

2010 ◽  
Vol 31 (10) ◽  
pp. 1758-1765 ◽  
Author(s):  
Majon Muller ◽  
Nicole Schupf ◽  
Jennifer J. Manly ◽  
Richard Mayeux ◽  
José A. Luchsinger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Elderly Men ◽  
Men And Women

Association of Lipidomics Signatures in Blood with Clinical Progression in Preclinical and Prodromal Alzheimer’s Disease

2021 ◽  
pp. 1-13
Author(s):  
Fatemah Sakr ◽  
Martin Dyrba ◽  
Anja U. Bräuer ◽  
Stefan Teipel ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Plasma Lipid ◽  
Optimal Number ◽  
Lipid Classes ◽  
Consensus Clustering ◽  
Clinical Progression ◽  
Clinical Dementia Rating ◽  
Prodromal Alzheimer’S Disease ◽  
Adjusted Model

Background: Lipidomics may provide insight into biochemical processes driving Alzheimer’s disease (AD) pathogenesis and ensuing clinical trajectories. Objective: To identify a peripheral lipidomics signature associated with AD pathology and investigate its potential to predict clinical progression. Methods: We used Bayesian elastic net regression to select plasma lipid classes associated with the CSF pTau/Aβ42 ratio as a biomarker of AD pathology in preclinical and prodromal AD cases from the ADNI cohort. Consensus clustering of the selected lipid classes was used to identify lipidomic endophenotypes and study their association with clinical progression. Results: In the APOE4-adjusted model, ether-glycerophospholipids, lyso-glycerophospholipids, free-fatty acids, cholesterol esters, and complex sphingolipids were found to be associated with the CSF pTau/Aβ 42 ratio. We found an optimal number of five lipidomic endophenotypes in the prodromal and preclinical cases, respectively. In the prodromal cases, these clusters differed with respect to the risk of clinical progression as measured by clinical dementia rating score conversion. Conclusion: Lipid alterations can be captured at the earliest phases of AD. A lipidomic signature in blood may provide a dynamic overview of an individual’s metabolic status and may support identifying different risks of clinical progression.

Effects of oestradiol on sex hormone binding globulin

1982 ◽  
Vol 101 (2) ◽  
pp. 248-253 ◽  
Author(s):  
Viveca Odlind ◽  
Kerstin Elamsson ◽  
Doris E. Englund ◽  
Arne Victor ◽  
Elof D. B. Johansson
Keyword(s):  
Luteal Phase ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Pronounced Increase ◽  
Menstrual Cycles ◽  
Menopausal Women ◽  
Plasma Oestradiol

Abstract. Sex hormone binding globulin (SHBG) levels were studied for possible effects of oestradiol-17β on SHBG. No change in SHBG plasma was recorded during normal menstrual cycles or during treatment with oestradiol-17β to menopausal women. However, gonadotrophin treatment to amenorrhoeic women to induce ovulation resulted in high oestradiol concentrations and a pronounced increase in SHBG was found during the luteal phase of these cycles. A marked increase of SHBG was also recorded in a woman with pronounced fluctuations of oestradiol during treatment with levonorgestrel sc implants for contraception. In conclusion, effects on SHBG were only found when extraordinarily high levels of plasma oestradiol were recorded.

Sex hormone-binding globulin (SHBG) and androgen levels in women with androgenetic alopecia

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S144 ◽  
Author(s):  
G. SINNECKER ◽  
E. LUDWIG ◽  
A. KRENZ ◽  
R.P. WILLIG
Keyword(s):  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Androgenetic Alopecia ◽  
Hormone Binding ◽  
Androgen Levels
Sign in / Sign up

Export Citation Format

Share Document